Detalles de la búsqueda
1.
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Blood
; 140(8): 839-850, 2022 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35605176
2.
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
Ann Hematol
; 103(2): 451-461, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38110588
3.
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 378(12): 1107-1120, 2018 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-29562156
4.
Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols.
Eur J Haematol
; 104(3): 162-169, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31724208
5.
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.
JAMA
; 322(2): 123-133, 2019 07 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31287523
6.
Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.
Blood Cells Mol Dis
; 68: 173-179, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27836529
7.
B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide.
Blood
; 137(16): 2267-2271, 2021 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33512465
8.
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Haematologica
; 103(7): 1209-1217, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29674504
9.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
N Engl J Med
; 370(12): 1101-10, 2014 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-24401022
10.
Patients with type 1 Gaucher disease in Spain: A cross-sectional evaluation of health status.
Blood Cells Mol Dis
; 56(1): 23-30, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26603719
11.
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Ann Hematol
; 94(8): 1347-56, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25975975
12.
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
Bone Marrow Transplant
; 59(3): 359-365, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38167647
13.
Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).
EClinicalMedicine
; 73: 102642, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38841711
14.
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
Blood
; 117(6): 1799-805, 2011 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-21148082
15.
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
Leukemia
; 37(2): 339-347, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36566271
16.
Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results.
Br J Haematol
; 157(1): 67-74, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22224845
17.
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.
Blood
; 115(25): 5137-46, 2010 Jun 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-20393132
18.
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.
Blood
; 116(25): 5650-9, 2010 Dec 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-20858857
19.
Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results.
Hemasphere
; 6(12): e801, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36398134
20.
Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
Blood Cells Mol Dis
; 46(1): 115-8, 2011 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20934891